We're raising our price target on Eli Lilly as the obesity-drug boom rolls on — ETFYield Lab Rate & Fee Analysis

We're raising our price target on Eli Lilly as the obesity-drug boom rolls on — ETFYield Lab Rate & Fee Analysis (ETFYield Lab Desk Note, 2026-11-03) — This briefing summarizes the supplied source material at https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html. Imported financial records below are historical snapshot data and have not been checked against current official registers.

Answer-First Summary: The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.

Imported Financial Source Snapshot (Not Independently Verified)#

The following fields are copied from an imported historical snapshot. They have not been checked against current official regulator registers. Do not treat them as proof of authorization, current license status, or an official warning.

• BOOM (Monex Boom Securities (H.K.) Limited) — Imported score: 6.5/10 | Imported risk field: unknown | Source license records: [SFC (unknown) License #AEF808 — regulated]

Core Analysis (ETFYield Lab Rate & Fee Analysis)#

The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.

Imported Financial Source Snapshot (Not Independently Verified)#

The following fields are copied from an imported historical snapshot. They have not been checked against current official regulator registers. Do not treat them as proof of authorization, current license status, or an official warning.

• BOOM (Monex Boom Securities (H.K.) Limited) — Imported score: 6.5/10 | Imported risk field: unknown | Source license records: [SFC (unknown) License #AEF808 — regulated]

Key Quantitative & Regulatory Takeaways#

• Primary Subject: We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
• Figures & Entities in Supplied Text: SFC
• Provided Source: Source link

Structured Fact & Metric Comparison Table#

Frequently Asked Questions (FAQ)#

What are the exact figures and regulatory details reported in We're raising our price target on Eli Lilly as the obesity-drug boom rolls on?#

The supplied text states: The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.

Imported Financial Source Snapshot (Not Independently Verified)#

The following fields are copied from an imported historical snapshot. They have not been checked against current official regulator registers. Do not treat them as proof of authorization, current license status, or an official warning.

• BOOM (Monex Boom Securities (H.K.) Limited) — Imported score: 6.5/10 | Imported risk field: unknown | Source license records: [SFC (unknown) License #AEF808 — regulated]

Has ETFYield Lab independently verified this tools data?#

No independent verification was performed by this rewrite step. The supplied source link is https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html.

Imported Financial Source Snapshot (Not Independently Verified)#

The following fields are copied from an imported historical snapshot. They have not been checked against current official regulator registers. Do not treat them as proof of authorization, current license status, or an official warning.

• BOOM (Monex Boom Securities (H.K.) Limited) — Imported score: 6.5/10 | Imported risk field: unknown | Source license records: [SFC (unknown) License #AEF808 — regulated]

Quantitative Verification & Analytical Model#